The Group's principal activities are the manufacturing, marketing and selling of medical implants based on the company's patented technology NASHA (Non-Animal Stabilized Hyaluronic Acid) to physicians, clinics and institutions. The Group operates through two segments: Esthetics and Hospital healthcare. The Esthetics segment manufactures products for the filling out of wrinkles and for the contouring of lips using Restylane. The Hospital healthcare segment manufactures products, which include ZUIDEX for the treatment of stress urinary incontinence in women, DEFLUX for the treatment of VUR (a malformation of the urinary bladder in children) and DUROLANE for the treatment of osteoarthritis of the knee and hip. The Group operates globally.
Alacra Alerts:
Receive alerts on the latest reports on Q-Med AB
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
